Campus Access Only
All rights reserved. This publication is intended for use solely by faculty, students, and staff of University of the Pacific. No part of this publication may be reproduced, distributed, or transmitted in any form or by any means, now known or later developed, including but not limited to photocopying, recording, or other electronic or mechanical methods, without the prior written permission of the author or the publisher.
Date of Award
1999
Document Type
Dissertation - Pacific Access Restricted
Degree Name
Doctor of Philosophy (Ph.D.)
Department
Pharmaceutical and Chemical Sciences
First Advisor
David Fries
Second Advisor
James Blankenship
First Committee Member
Madhukar Chaubal
Second Committee Member
Patrick Jones
Third Committee Member
Alice Matuszak
Abstract
Acetylated polyamines, N 1 - and N 8 -acetylspermidine, are key intermediates in polyamine metabolism. Hexamethylenebisacetamide (HMBA) is a synthetic polyamine derivative known to induce in vitro biochemical and morphological differentiation of murine and human tumor cell lines. Deacetylation of HMBA and/or its metabolite N-acetyl-1,6-diaminohexane (NADAH) has been suggested to be catalyzed by N 8 -acetylspermidine deacetylase, a cytoplasmic enzyme involved in polyamine metabolism. The present investigation is focused on (1) the effect of N 1 - and N 8 -acetylspermidines, HMBA and NADAH on differentiation in Cloudman S91 melanoma cells, and (2) the effect of 7-[N-(3-aminopropyl)amino]heptan-2-one (APAH), a N 8 -acetylspermidine deacetylase inhibitor, on the effects of N 8 -acetylspermidine, HMBA, and NADAH on differentiation in Cloudman S91 melanoma cells. The biochemical signs of differentiation were measured as melanin content (absorbance at 475 nm) and tyrosinase activity (release of 3 H 2 O from 3 H-tyrosine) per μg protein. α-Melanocyte stimulating hormone (α-MSH) was used as a positive control. After 4 days of treatment, MSH at 100 nM raised the melanin to 293% of control (p < 0.05) and tyrosinase activity to 550% of control (p < 0.05). Spermidine did not produce any significant effect on these parameters in S91 cells. N 1 -acetylspermidine increased tyrosinase activity only at higher concentrations (100 and 1000 μM). However, 24-hour treatment of N 8 -acetylspermidine produced a dose dependent differentiation of S91 cells. At 10 −4 M, N 8 -acetylspermidine increased melanin by 85% and tyrosinase activity by more than 150% of control (p < 0.05). APAH alone had moderate effect on differentiation but potentiated and prolonged the effects produced by N 8 -acetylspermidine. HMBA decreased both melanin and tyrosinase activity in a dose dependent manner. After 4 days of treatment, 3 mM HMBA reduced melanin to 60% of control (p < 0.05) and tyrosinase activity to 4% of control (p < 0.05). NADAH is more active than HMBA. APAH was able to reduce the effects of HMBA (but not those of NADAH) on the parameters of differentiation. The results from the present study suggest that N 8 -acetylspermidine and HMBA have opposite effects on differentiation of S91 cells. The inability of APAH to counter NADAH-mediated decrease in tyrosinase activity suggests that APAH may be blocking the deacetylation of NADAH to an inactive metabolite.
Pages
134
ISBN
0599419210 , 9780599419216
Recommended Citation
Malladi, Ramana Rao. (1999). Effects of acetylated polyamines on differentiation of Cloudman S91 melanoma cells. University of the Pacific, Dissertation - Pacific Access Restricted. https://scholarlycommons.pacific.edu/uop_etds/2638
To access this thesis/dissertation you must have a valid pacific.edu email address and log-in to Scholarly Commons.
Find in PacificSearch Find in ProQuestIf you are the author and would like to grant permission to make your work openly accessible, please email
Rights Statement
In Copyright. URI: http://rightsstatements.org/vocab/InC/1.0/
This Item is protected by copyright and/or related rights. You are free to use this Item in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you need to obtain permission from the rights-holder(s).